SCHEMBL1704580

SCHEMBL1704580

COC(=O)C(C)(C)c1ccc(CN2C[C@@H](C)N(C(=O)OC(C)(C)C)[C@@H](C)C2)cc1

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MLNR O43193 2/20 0.41
CYP3A4 P08684 1/20 0.41
S1PR1 P21453 4/20 0.39
HSD11B1 P28845 1/20 0.38
HDAC1 Q13547 3/20 0.38
HDAC6 Q9UBN7 3/20 0.38
BRS3 P32247 1/20 0.37
JAK1 P23458 1/20 0.37
S1PR4 O95977 1/20 0.36
S1PR5 Q9H228 1/20 0.36
DRD2 P14416 1/20 0.36
DRD4 P21917 1/20 0.36
CACNA1G O43497 2/20 0.36
GPR119 Q8TDV5 1/20 0.35
KDM4E B2RXH2 1/20 0.35
ALDH1A1 P00352 1/20 0.35
MAPT P10636 1/20 0.35
RAB9A P51151 1/20 0.35
RORC P51449 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1704169 0.89 HRH3 (0.44) MLNRCYP3A4S1PR1HSD11B1HDAC1
SCHEMBL4595783 0.89 HRH3 (0.44) MLNRCYP3A4S1PR1HSD11B1HDAC1
SCHEMBL4188128 0.87 MLNR (0.42) MLNRCYP3A4S1PR1HDAC1HDAC6
SCHEMBL31096238 0.84 GPR119 (0.42) S1PR1HSD11B1HDAC1HDAC6JAK1
SCHEMBL377504 0.83 PTPN2 (0.39) MLNRCYP3A4HDAC1HDAC6JAK1
SCHEMBL1703945 0.83 KCNK3 (0.44) S1PR1HDAC1HDAC6GPR119KDM4E
SCHEMBL377569 0.83 GBA1 (0.41) S1PR1HSD11B1JAK1S1PR5GPR119
SCHEMBL23257920 0.81 VEGFA (0.50) HDAC1HDAC6CACNA1GALDH1A1MAPT
SCHEMBL11978840 0.81 HDAC1 (0.36) S1PR1HSD11B1HDAC1HDAC6JAK1
SCHEMBL3660136 0.81 CHRM4 (0.41) S1PR1HSD11B1HDAC1HDAC6JAK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2441763-A1 Benzylpiperazine derivatives useful for the treatment of gastrointestinal disorders Glaxo Group Limited (GB) 2012-04-18 EP disclosed